研究Cxcl14在慢性重症心脏功能障碍中的作用和机制
Yongke Zheng1, Nanyuan Gu2, Kai Qiu2
1Department of Rehabilitation, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, 261 Huansha Road, 310006, Hangzhou, Zhejiang, China.
Biochemical and biophysical research communications
|February 26, 2025
概括
化学Cxcl14通过促进炎症和纤维化,在慢性严重疾病 (CCI) 中恶化心脏功能障碍. 中和Cxcl14为CCI相关心力衰竭提供了潜在的治疗策略.
科学领域:
- 心血管医学 心血管医学
- 免疫学 免疫学 免疫学
- 关键护理医学 关键护理医学
背景情况:
- 慢性严重疾病 (CCI) 与显著的心脏功能障碍有关.
- 在CCI引起的心脏问题背后的具体机制需要进一步阐明.
研究的目的:
- 调查化学Cxcl14 (Cxcl14) 在CCI患者心脏功能障碍中的作用和机制.
- 探索Cxcl14作为CCI相关心脏功能障碍的潜在治疗点.
主要方法:
- 对有心力衰竭和没有心力衰竭的CCI患者的临床数据分析.
- 血清Cxcl14水平的ELISA量化.
- 建立一个CCI小鼠模型 (CLP) 来评估心脏功能,心肌损伤,炎症和纤维化.
- 在小鼠模型中评估抗Cxcl14抗体的治疗效果.
主要成果:
- 在CCI患者中,血清Cxcl14水平与N-终端前脑尿素 (NT-proBNP) 呈正相关,与左心室喷射分数 (LVEF) 呈负相关.
- 在CLP模型中,Cxcl14降低了LVEF和左心室内膜缩短分数 (LVFS),增加了心肌纤维化标志物 (α-SMA,原III),并促进了炎症细胞透 (ED-1,MPO,TNF-α,IL-6).
- 服用抗Cxcl14抗体改善了CCI诱导的心脏功能障碍.
结论:
- 在CCI中,Cxcl14表达与心脏功能障碍的发病和严重程度有关.
- 在CCI小鼠模型中,Cxcl14加剧心肌损伤和纤维化,同时促进炎症.
- 用抗体准Cxcl14是一个有希望的治疗途径,用于管理CCI中的心脏功能障碍.
更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
41
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
41
01:29Pathophysiology of Cardiac Performance
509
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
509
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370